Drug class profile · refreshed daily from federal data

Carbonic Anhydrase Inhibitor

7 molecules in this class, $167.6M combined CY2024 Part D spend across 2.4M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Carbonic Anhydrase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 7tracked in Part D
CY24 Part D spend: $167.6Mcombined across class
Total Rx claims: 2.4M882K unique beneficiaries
Generic mfrs (active): 39across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Brinzolamide

Brand: Azopt · 332K Part D claims (CY24) · 113K beneficiaries · First FDA approval: 1998-04-30

2 generic mfrs 0 plans require PA

Low NADAC$10.02

→

Avg plan cost$15.18

Part D spend $75.2M 2× spread, current vs floor

Class share

45%

of class CY24 spend

View profile →

Dichlorphenamide

Brand: Keveyis · 1K Part D claims (CY24) · 230 beneficiaries · First FDA approval: 2021-12-13

2 generic mfrs 44 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $37.3M

Class share

22%

of class CY24 spend

View profile →

Dorzolamide

Brand: Dorzolamide Hydrochloride · 1.6M Part D claims (CY24) · 539K beneficiaries · First FDA approval: 2009-06-01

9 generic mfrs 0 plans require PA

Low NADAC$0.858

→

Avg plan cost$0.858

Part D spend $32.3M 1× spread, current vs floor

Class share

19%

of class CY24 spend

View profile →

Acetazolamide

Brand: Acetazolamide · 507K Part D claims (CY24) · 230K beneficiaries · First FDA approval: 1996-05-01

26 generic mfrs 0 plans require PA

Low NADAC$0.096

→

Avg plan cost$0.159

Part D spend $22.7M 2× spread, current vs floor

Class share

14%

of class CY24 spend

View profile →

Acetazolamide Extended-Release

— Part D claims (CY24) · First FDA approval: 2020-12-01

Brand-only (no generics)

Low NADAC$0.275

→

Avg plan cost$0.275

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Brinzolamide and Brimonidine

Brand: SIMBRINZA · — Part D claims (CY24) · First FDA approval: 2013-05-06

Brand-only (no generics) 2 plans require PA

Low NADAC$26.04

→

Avg plan cost$26.04

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Dorzolamide and Timolol

Brand: COSOPT · — Part D claims (CY24) · First FDA approval: 2009-07-14

Brand-only (no generics) 0 plans require PA

Low NADAC$0.916

→

Avg plan cost$4.02

Part D spend — 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.